AssetMark Inc
AUPH icon

AssetMark Inc’s Aurinia Pharmaceuticals AUPH Stock Holding History

AssetMark Inc’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.96K Sell
183
-21
-10% -$335 ﹤0.01% 2927
2026
Q2 		$3.46K Buy
204
+81
+66% +$1.29K ﹤0.01% 2812
2026
Q1 		$1.82K Hold
123
– – ﹤0.01% 2883
2025
Q4 		$1.96K Hold
123
– – ﹤0.01% 2780
2025
Q3 		$1.36K Buy
+123
New +$1.34K ﹤0.01% 2721

Other funds holding AUPH

LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ritholtz Wealth Management
Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

AssetMark Inc's AUPH Position: Q3 2026 in Review

AssetMark Inc reduced its Aurinia Pharmaceuticals (AUPH) stake by 10% in Q3 2026, selling an estimated $335 and leaving 183 shares worth $2.96K. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

AssetMark Inc first reported a position in AUPH in Q3 2025 and has held it in 5 quarters since. The position peaked at $3.46K in Q2 2026. 102 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • AssetMark Inc held 183 shares of Aurinia Pharmaceuticals worth $2.96K as of Q3 2026.
  • AssetMark Inc sold 21 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $335.
  • Aurinia Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #2927 holding.
  • AssetMark Inc first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • AssetMark Inc's Aurinia Pharmaceuticals position peaked at $3.46K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.